Chemomab Therapeutics Ltd
CMMB
Company Profile
Business description
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
Contact
Kiryat Atidim
Building 7
Tel Aviv6158002
ISRT: +972 773310156
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,475.20 | 12.60 | 0.15% |
| CAC 40 | 7,743.75 | 49.31 | 0.64% |
| DAX 40 | 23,499.32 | 146.63 | 0.63% |
| Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
| FTSE 100 | 8,554.80 | 23.19 | 0.27% |
| HKSE | 23,114.31 | 246.57 | 1.08% |
| NASDAQ | 17,928.92 | 0.78 | 0.00% |
| Nikkei 225 | 37,612.90 | 109.57 | 0.29% |
| NZX 50 Index | 12,676.75 | 71.68 | 0.57% |
| S&P 500 | 5,659.91 | 4.03 | -0.07% |
| S&P/ASX 200 | 8,242.80 | 11.60 | 0.14% |
| SSE Composite Index | 3,356.98 | 14.98 | 0.45% |